{
    "symbol": "NTNX",
    "quarter": 1,
    "year": 2023,
    "date": "2022-11-30 21:06:02",
    "content": " During today\u00e2\u0080\u0099s call, management will make forward-looking statements, including statements regarding our business plans, strategies, initiatives, vision, objectives and outlook including our financial guidance as well as our ability to execute hereon successfully and in a timely manner and the benefits and impact thereof on our business, operations and financial results, our financial performance and targets and use of new or different performance metrics in future periods, expectations regarding profitability, our competitive position and market opportunity, the timing and impact of our current and future business model transitions, the factors driving our growth, macroeconomic, geopolitical and industry trends, including global supply chain challenges and the current and anticipated impact of the COVID-19 pandemic and related effects. ACV billings in Q1 was $232 million, higher than our guidance of $210 million to $215 million and representing a year-over-year growth of 27%. The guidance for Q2 \u00e2\u0080\u009823 is as follows: ACV billings of $245 million to $260 million, implying a year-over-year growth rate of 13% at the midpoint. Revenue of $460 million to $470 million, a year-over-year growth of 13% at the midpoint, non-GAAP gross margin of 82% to 83%, non-GAAP operating margin of approximately 5% to 10%, weighted average shares outstanding of approximately 279 million shares. Our guidance for full year fiscal year 2023 is as follows: ACV billings guidance remains unchanged at $895 million to $900 million, year-over-year growth of 19% at the midpoint. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}